We are live on ! Find out more
HQL

abrdn Life Sciences Investors

73 hedge funds and large institutions have $147M invested in abrdn Life Sciences Investors in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

4% more capital invested

Capital invested by funds: $142M → $147M (+$5.63M)

1.25% less ownership

Funds ownership: 31.69%30.44% (-1.3%)

12% less funds holding

Funds holding: 8373 (-10)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
73
Holders Change
-10
Holders Change %
-12.05%
% of All Funds
0.89%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
28
Reduced
20
Closed
19
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q4 2025 in Review

73 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2025, worth a combined $147M — up 4% from $142M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of HQL and 11 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 28 added.

The largest buyer was Morgan Stanley, adding an estimated $4.94M. The largest seller was Saba Capital Management, cutting an estimated $7.89M.

  • 73 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2025, down from 83 in Q3 2025.
  • Funds reported $147M of abrdn Life Sciences Investors stock for Q4 2025, up 4% quarter-over-quarter.
  • 11 funds opened new abrdn Life Sciences Investors positions in Q4 2025 and 19 closed out, a net change of -8 holders.
  • The largest abrdn Life Sciences Investors buyer in Q4 2025 was Morgan Stanley, an estimated $4.94M added.
  • The largest abrdn Life Sciences Investors seller in Q4 2025 was Saba Capital Management, an estimated $7.89M sold.

Based on aggregated 13F filings for Q4 2025.